Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

Overview

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention. However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.

Full Title of Study: “Prevalence of Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal in Non-valvular Atrial Fibrillation Patients—- A Study in Hong Kong General Out-patient Clinic”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 23, 2020

Interventions

  • Other: no intervention
    • no intervention

Clinical Trial Outcome Measures

Primary Measures

  • The prevalence of anticoagulant use in non-valvular atrial fibrillation patients
    • Time Frame: August 2019 to March 2020
    • calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients

Secondary Measures

  • the rate of the refusal of anticoagulant use
    • Time Frame: August 2019 to March 2020
    • calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosis as atrial fibrillation – aged ≧18 years – able to given consent Exclusion Criteria:

  • Unable/unwillingness to sign informed consent to study – mechanical heart valve – moderate-to-severe mitral stenosis – Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm) – pregnancy – hospitalization within 1 month prior to inclusion in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Prince of Wales Hospital, Shatin, Hong Kong
  • Provider of Information About this Clinical Study
    • Principal Investigator: chen liujing, resident – Prince of Wales Hospital, Shatin, Hong Kong

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.